Stool Biomarker Monitoring for Early NEC Risk in Premature Newborns
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing necrotizing enterocolitis (NEC) in premature newborns are not highly specific and sensitive, leading to delayed detection and challenging treatment, with a need for a prompt and effective method to monitor bowel health and prevent inflammation and infection.
Innovation Solution
A method involving stool sample analysis through microbiomics, automated cell counting, flow cytometry, and RNA transcriptomics to evaluate gut health, identifying inflammatory conditions and NEC risk by analyzing neutrophil and macrophage percentages, and gene expression profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods (physical examination, blood tests, fecal tests, abdominal X-ray) are used to diagnose NEC, then the diagnosis can be made, but the sensitivity and specificity are insufficient and detection is delayed
Solution Approach 1:
The patent performs stool microbiomics analysis, cell counting, flow cytometry, and RNA transcriptomics on stool samples collected before NEC symptoms fully manifest. By analyzing bacterial composition, immune cell percentages (neutrophils, lymphocytes, macrophages), and gene expression profiles in advance, the method detects subtle changes that precede clinical diagnosis, enabling early intervention before tissue necrosis occurs
Solution Approach 2:
The patent replaces traditional mechanical/physical diagnostic methods (abdominal X-ray, physical examination) with advanced molecular and cellular analysis techniques. Specifically, it uses microbiomics sequencing, flow cytometry, and RNA transcriptomics to detect biological markers of NEC at a molecular level, providing higher sensitivity and earlier detection than conventional imaging and physical methods
2Reliability
If multiple tests are conducted to determine therapeutic strategies, then treatment can be optimized, but the complexity and time required for diagnosis increases
Solution Approach 1:
The patent divides the diagnostic workup into four distinct analytical modules: microbiomics analysis (bacterial composition), automated cell counting (neutrophil/lymphocyte ratios), flow cytometry (macrophage activation status), and RNA transcriptomics (gene expression profiles). Each module provides specific information about different aspects of bowel health and inflammation, allowing systematic evaluation without overwhelming complexity
Solution Approach 2:
The patent uses stool samples as a universal diagnostic medium that can simultaneously provide information about bacterial composition, immune cell status, and gene expression. This single sample type serves multiple diagnostic purposes, eliminating the need for multiple separate invasive tests and simplifying the overall diagnostic workflow while maintaining comprehensive assessment capability
3Measurement precision
If blood and stool tests along with abdominal X-ray are used, then the seriousness of condition can be determined, but the specificity for NEC versus other clinical conditions is insufficient
Solution Approach 1:
The patent focuses analysis specifically on stool-based markers that are locally produced or present in the gastrointestinal tract, rather than using systemic blood markers. By analyzing bacterial composition, stool cell counts, and gene expression profiles specific to the gut environment, the method identifies NEC with higher specificity, as these local markers are less likely to be affected by systemic conditions like sepsis that can cause non-specific blood marker changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and prevention of NEC, facilitating timely therapy to reduce morbidity and mortality in premature infants, providing a non-invasive and rapid assessment of bowel health.
Implementation Method 1
subjecting the first portion of the stool/fecal sample to density gradient centrifugation to separate white blood cells
Implementation Method 2
a second sub portion of the PBS-diluted sample is subjected to density gradient centrifugation and flow cytometric analysis to determine percentages of specific cell types
Data Source
AI summary
Disclosed is a method for monitoring and evaluation of bowel health in premature newborns. The method involves collecting stool/fecal samples from premature newborns/babies and processing the sample using microbiomics, automated cell counting, flowcytometry, and RT PCR analysis using specific gene signature or RNA transcriptomics analysis to determine risk of necrotizing enterocolitis. The method allows evaluation and tracking of gut health without needing to draw a blood test and is a non-invasive method. The method diagnoses and prevents bowel inflammation, infection and necrotizing enterocolitis (NEC) that facilitates initiation of prompt therapy to limit morbidity and mortality in premature babies. The method facilitates early management of signs of NEC thereby helping to save lives of premature babies and infants having low birth weight.